Pliant Therapeutics Announces Appointment of Gregory P. Cosgrove, M.D., FCCP, as Vice President of Clinical Development, IPF
Pliant Therapeutics, Inc. (PLRX)
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the appointment of Gregory P. Cosgrove, M.D., FCCP, as Pliant’s Vice President of Clinical Development. Dr. Cosgrove brings over 20 years of pulmonary and critical care expertise in academic clinical research to Pliant and in this role, will lead the strategic execution of the company’s Idiopathic Pulmonary Fibrosis (IPF) clinical development program with its lead compound PLN-74809. PLN-74809 is a dual selective inhibitor of avß6/avß1, in clinical development for the treatment of IPF, primary sclerosing cholangitis (PSC), and COVID-19-associated acute respiratory distress syndrome (ARDS). "Greg’s extensive scientific and clinical expertise in the area of pulmonary fibrosis, as well as his strong relationships within the research, clinic
Show less
Read more
Impact Snapshot
Event Time:
PLRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLRX alerts
High impacting Pliant Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PLRX
News
- Pliant Therapeutics to Participate in Upcoming Investor EventsGlobeNewswire
- Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.MarketBeat
- Pliant Therapeutics to Participate in Upcoming Investor EventsGlobeNewswire
- Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference [Yahoo! Finance]Yahoo! Finance
- Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International ConferenceGlobeNewswire
PLRX
Earnings
- 11/9/23 - Beat
PLRX
Sec Filings
- 4/22/24 - Form DEFA14A
- 4/22/24 - Form DEF
- 3/12/24 - Form 8-K
- PLRX's page on the SEC website